- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
ARS Pharmaceuticals, based in San Diego, submitted a generic product application requiring FDA approval.
1 report, 1 independent
Updated Sep 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ARS Pharmaceuticals, based in San Diego, submitted a generic product application requiring FDA approval.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- Fate Therapeutics, based in San Diego, is seeking support for an accelerated regulatory pathway from the FDA.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- Future sales of a product are contingent upon obtaining the necessary FDA registration and labeling, while the state simultaneously announces actions to remove regulatory barriers.
- A product, NitroMist®, requires FDA approval for sale, and distributor access is being established for federal supply channels.
- Biocon's subsidiary received FDA approval for a drug in the United States on August 18, 2026.
Coverage
Newest first; wire copies grouped- Insider MonkeyARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDA ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is among the fastest growing small cap stocks to buy. Lupin Inc., a leading player in the heal